At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 49 enrolled
Drug / intervention
Inhaled nitric oxide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Double-blind Placebo-controlled Trial of Inhaled Nitric Oxide for the Treatment of Microcirculatory Dysfunction and Organ Failure in Sepsis
National Institute of General Medical Sciences (NIGMS)·interventional·Posted Feb 6, 2008·Updated Jul 11, 2013
In Brief
A Phase 3 clinical trial evaluating Inhaled nitric oxide and Sham inhaled nitric oxide for Sepsis. Completed, enrolled 49 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether inhaled nitric oxide is an effective treatment for microcirculatory dysfunction and acute organ system failure in the early stage of sepsis therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSepsis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2008
Enrollment StartAug 2009
Primary CompletionApr 2013
TodayJul 2026
First PostedFeb 6, 2008
Enrollment StartAug 1, 2009
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 18.4 years ago
Interventions
Inhaled nitric oxidedrug
Inhaled nitric oxide, 40 parts per million, for six hours.
Sham inhaled nitric oxideother
Sham inhaled nitric oxide administration, 0 parts per million, for six hours.